Gilead Sciences (GILD) is preparing to lay off approximately 20% of its sales force now that two of its older drugs have lost patent protection and face competition from lower-priced generics, STAT has learned.

The decision to cut 150 long-tenured sales people — confirmed by a Gilead spokesperson — is being explained internally as an unfortunate but necessary cost-cutting move. But to some Gilead employees, the firings are another worrisome sign that the company’s executive team, led by recently appointed CEO Daniel O’Day, is struggling to find ways to grow revenue and earnings.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy